388 related articles for article (PubMed ID: 3612128)
21. Interaction of GM2 activator protein with glycosphingolipids.
Hama Y; Li YT; Li SC
J Biol Chem; 1997 Jan; 272(5):2828-33. PubMed ID: 9006924
[TBL] [Abstract][Full Text] [Related]
22. Ganglioside accumulation in cultured skin fibroblasts from gangliosidosis patients.
Pullarkat RK; Reha H; Beratis NG
Biochem Biophys Res Commun; 1980 Jan; 92(1):149-54. PubMed ID: 7356448
[No Abstract] [Full Text] [Related]
23. GM2 ganglioside in fetal Tay-Sachs disease brain cultures: a model system for the disease.
Hoffman LM; Amsterdam D; Schneck L
Brain Res; 1976 Jul; 111(1):109-17. PubMed ID: 953690
[TBL] [Abstract][Full Text] [Related]
24. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
Tsuji D
Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
[TBL] [Abstract][Full Text] [Related]
25. Presence of an unusual GM2 derivative, taurine-conjugated GM2, in Tay-Sachs brain.
Li YT; Maskos K; Chou CW; Cole RB; Li SC
J Biol Chem; 2003 Sep; 278(37):35286-91. PubMed ID: 12829702
[TBL] [Abstract][Full Text] [Related]
26. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases.
Ou L; Przybilla MJ; Tăbăran AF; Overn P; O'Sullivan MG; Jiang X; Sidhu R; Kell PJ; Ory DS; Whitley CB
Gene Ther; 2020 May; 27(5):226-236. PubMed ID: 31896760
[TBL] [Abstract][Full Text] [Related]
27. Brain ceramide hexosides in Tay-Sachs disease and generalized gangliosidosis (GM1-gangliosidosis).
Suzuki K; Chen GC
J Lipid Res; 1967 Mar; 8(2):105-13. PubMed ID: 14564716
[TBL] [Abstract][Full Text] [Related]
28. GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease.
Demir SA; Timur ZK; Ateş N; Martínez LA; Seyrantepe V
J Neuroinflammation; 2020 Sep; 17(1):277. PubMed ID: 32951593
[TBL] [Abstract][Full Text] [Related]
29. High-resolution loading tests in the study of genetic heterogeneity in gangliosidosis fibroblasts.
Akhunov VS; Mirenburg TV; Krasnopolskaya XD
J Inherit Metab Dis; 1994; 17(1):104-11. PubMed ID: 8051915
[TBL] [Abstract][Full Text] [Related]
30. [Biosynthesis and biodegradation of GM2 ganglioside].
Hirabayashi Y; Kasakura H; Matsumoto M
Tanpakushitsu Kakusan Koso; 1984 Sep; 29(9):708-22. PubMed ID: 6240072
[No Abstract] [Full Text] [Related]
31. Assay of the GM2-ganglioside cleaving hexosaminidase activity of skin fibroblasts for GM2-gangliosidoses.
Harzer K
Clin Chim Acta; 1983 Nov; 135(1):89-93. PubMed ID: 6228344
[No Abstract] [Full Text] [Related]
32. Therapeutic evaluation of GM2 gangliosidoses by ELISA using anti-GM2 ganglioside antibodies.
Tsuji D; Higashine Y; Matsuoka K; Sakuraba H; Itoh K
Clin Chim Acta; 2007 Mar; 378(1-2):38-41. PubMed ID: 17196574
[TBL] [Abstract][Full Text] [Related]
33. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
Baek RC; Kasperzyk JL; Platt FM; Seyfried TN
Neurochem Int; 2008 May; 52(6):1125-33. PubMed ID: 18207611
[TBL] [Abstract][Full Text] [Related]
34. Evidence for direct binding of intracellularly distributed ganglioside GM2 to isolated vimentin intermediate filaments in normal and Tay-Sachs disease human fibroblasts.
Kotani M; Hosoya H; Kubo H; Itoh K; Sakuraba H; Kusubata M; Inagaki M; Yazaki S; Suzuki Y; Tai T
Cell Struct Funct; 1994 Apr; 19(2):81-7. PubMed ID: 7923401
[TBL] [Abstract][Full Text] [Related]
35. Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease.
Seyrantepe V; Demir SA; Timur ZK; Von Gerichten J; Marsching C; Erdemli E; Oztas E; Takahashi K; Yamaguchi K; Ates N; Dönmez Demir B; Dalkara T; Erich K; Hopf C; Sandhoff R; Miyagi T
Exp Neurol; 2018 Jan; 299(Pt A):26-41. PubMed ID: 28974375
[TBL] [Abstract][Full Text] [Related]
36. Glycosphingolipid degradation and animal models of GM2-gangliosidoses.
Kolter T; Sandhoff K
J Inherit Metab Dis; 1998 Aug; 21(5):548-63. PubMed ID: 9728335
[TBL] [Abstract][Full Text] [Related]
37. Characterization of neutral and acidic glycosphingolipids in brains of two patients with GM1 gangliosidosis type 1 and type 2.
Ishikawa Y; Makita A; Minami R
J Neurochem; 1985 Apr; 44(4):1100-6. PubMed ID: 3919156
[TBL] [Abstract][Full Text] [Related]
38. Accumulation of ganglioside Gm2 in cerebrospinal fluid of a patient with the variant AB of infantile Gm2 gangliosidosis.
Pullarkat RK; Reha H; Beratis NG
Pediatrics; 1981 Jul; 68(1):106-8. PubMed ID: 7243492
[TBL] [Abstract][Full Text] [Related]
39. Effective gene therapy in an authentic model of Tay-Sachs-related diseases.
Cachón-González MB; Wang SZ; Lynch A; Ziegler R; Cheng SH; Cox TM
Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10373-10378. PubMed ID: 16801539
[TBL] [Abstract][Full Text] [Related]
40. Characterization of inducible models of Tay-Sachs and related disease.
Sargeant TJ; Drage DJ; Wang S; Apostolakis AA; Cox TM; Cachón-González MB
PLoS Genet; 2012 Sep; 8(9):e1002943. PubMed ID: 23028353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
